Aims-To assess the consistency and reproducibility of assessment of c-erbB-2 immunostaining, and to examine some of the problems relating to inter-and intraobserver variability in the documentation of positive staining; to profile the spectrum of cytoplasmic and membranous staining in a wide range of tumour types. Methods-A total of 283 neoplasms were examined for immunohistochemical expression of the c-erbB-2 oncoprotein. Three independent observers were required to assess intensity both of membrane and cytoplasmic staining on a three point and then a four point scale. Extent of positive staining was also assessed on a two point scale. A minimum of two weeks elapsed between assessments using the differing scales.
types. Methods-A total of 283 neoplasms were examined for immunohistochemical expression of the c-erbB-2 oncoprotein. Three independent observers were required to assess intensity both of membrane and cytoplasmic staining on a three point and then a four point scale. Extent of positive staining was also assessed on a two point scale. A minimum of two weeks elapsed between assessments using the differing scales. Results-Positive membrane staining was documented by one or more observers in 16 -6% of tumours examined. This positivity was largely restricted to bladder, renal, and breast tumours. The overall level of disagreement as to the presence or absence of membranous staining was 11*3%. Cytoplasmic staining was identified in 55 5% of tumours studied. The level of disagreement as to the presence or absence of cytoplasmic staining was 26*5%.
Conclusions-Intraobserver variability was minimal, indicating that each pathologist was adhering to internal reproducible standards. Interobserver variability was greater, indicating that the interpretation of c-erbB-2 inmunostaning may require set guidelines. It is suggested that assessment should be referenced to a standard positive control, that a three tier system for grading of intensity and a two tier system for grading of extent should be adopted, and that the evaluation should be agreed by at least two pathologists. The presence of cytoplasmic staining should continue to be routinely recorded until its biological role and clinical implications are filly understood. (7 Clin Pathol 1994; 47:816-822) The c-erbB-2 proto-oncogene is thought to have a role in normal cell proliferation and development. The gene is located on chromosome 17 (q21), encodes a 46 kilobase mRNA, and produces a 185 kilodalton glycoprotein. This protein product is a transmembrane receptor with tyrosine kinase activity and shows 78% homology with the intracytoplasmic domain of the epidermal growth factor receptor. '-" Amplification and overexpression of the proto-oncogene c-erbB-2 (HER2/neu) has been reported in a wide variety of tumour types, predominantly of epithelial origin, including female breast,' 2-18 ovary,"3 transitional cell carcinoma (TCC),'920 pancreas,2' stomach,22 23 kidney,24 25 and salivary gland. 26 27 In contrast, it is rarely described in other epithelial tissues28 or mesenchymal neoplasms, such as cartilage. 29 Despite this impressive list of human tumours studied, the clinical relevance of some of the results in terms of prognosis is uncertain [30] [31] [32] 30 in their study of breast carcinomas. In this department a similar study of c-erbB-2 staining in breast carcinoma showed some positivity in 26% of cases (unpublished observations).
How should these variations in results be interpreted? In this department three large multivariate studies are in train and in each study the prognostic value of c-erbB-2 immunoreactivity is being assessed. However, in the course of these studies each investigator encountered problems with the interpretation of the staining reaction.
This prompted the current study in which we sought to examine some of the problems relating to inter-and intraobserver variability in the documentation of positive staining. We also profiled the spectrum of cytoplasmic and membranous staining in a wide range of tumours, some of which had never been examined before, for the presence of c-erbB-2 oncogene expression. (4) 27 33 38 40 4357 Our ability accurately to compare results is hindered by the lack of detail recorded in terms of staining type, intensity, extent and location. In those tumour types where our results are at variance with those reported, the possibility that the findings may be accentuated in our own laboratory is raised. The way to explore this would be to repeat the study using tumours stained in other laboratories. However, as many of the other tumour groups demonstrated a level of positivity similar to those of other published studies, the likelihood of our methodology being solely at fault is not very high. Much remains to be elucidated regarding the role of c-erbB-2 in tumour biology and its value as a prognostic indicator seems to be restricted to a few tumour types. Although speculative, perhaps its greatest application will be as one of a panel of oncogene markers as is the situation with other immunohistochemical agents.
